Halozyme to Report First Quarter 2024 Financial and Operating Results

Rhea-AI Summary

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will report its first quarter 2024 financial and operating results on May 7, 2024. The company will host a conference call to discuss the results on the same day.

SAN DIEGO, April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.

Halozyme will host a conference call on Tuesday, May 7, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871907.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Samantha Gaspar 
Teneo
617-877-9710
samantha.gaspar@teneo.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-first-quarter-2024-financial-and-operating-results-302124221.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme report its first quarter 2024 financial and operating results?

Halozyme will report its first quarter 2024 financial and operating results on May 7, 2024.

What is the ticker symbol for Halozyme Therapeutics, Inc.?

The ticker symbol for Halozyme Therapeutics, Inc. is HALO.

How can I access the live conference call to discuss the results?

The live conference call to discuss the results can be accessed with pre-registration via this link: https://registrations.events/direct/Q4I871907.

Where can I find the webcast and replay of the conference call?

The webcast and replay of the conference call will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.